Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

5.4.99.7: Lanosterol synthase

This is an abbreviated version!
For detailed information about Lanosterol synthase, go to the full flat file.

Word Map on EC 5.4.99.7

Reaction

(3S)-2,3-epoxy-2,3-dihydrosqualene
=
lanosterol

Synonyms

2,3 oxidosqualene:lanosterol cyclase, 2,3-Epoxysqualene lanosterol-cyclase, 2,3-epoxysqualene--lanosterol cyclase, 2,3-Epoxysqualene-lanosterol cyclase, 2,3-Oxidosqualene cyclase, 2,3-oxidosqualene cyclase-lanosterol synthase, 2,3-Oxidosqualene sterol cyclase, 2,3-Oxidosqualene-lanosterol cyclase, 2,3-oxidosqualene:lanosterol cyclase, AtLAS, Cyclase, 2,3-oxidosqualene-lanosterol, ERG7, Erg7p, hOSC, Lanosterol 2,3-oxidosqualene cyclase, lanosterol synthase, LAS, LAS1, Lss, OSC, OSLC, Oxidosqualene cyclase, oxidosqualene cyclase/lanosterol synthase, Oxidosqualene--lanosterol cyclase, Oxidosqualene-lanosterol cyclase, oxidosqualene:lanosterol cyclase, SceOSC, Squalene 2,3-epoxide:lanosterol cyclase, Squalene 2,3-oxide-lanosterol cyclase, Squalene epoxidase-cyclase, Squalene-2,3-oxide-lanosterol cyclase, tuber-specific StLAS-like

ECTree

     5 Isomerases
         5.4 Intramolecular transferases
             5.4.99 Transferring other groups
                5.4.99.7 Lanosterol synthase

Engineering

Engineering on EC 5.4.99.7 - Lanosterol synthase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
H232S
-
site-directed mutagenesis, mutant energy profile compared to the wild-type enzyme
H232T
-
site-directed mutagenesis, mutant energy profile compared to the wild-type enzyme
N478H/V482I
-
change of amino acids crucial for specificity to the cycloartenol synthase type. Mutant produces 4% lanosterol, 83% parkeol, and 13% cycloartenol from substrate (S)-2,3-epoxysqualene
D139N
reduced activity
D139N/G189A/Q481R
induces cataracts in rats, produces only 39% of the lanosterol produced by wild-type
H469-C472del
deletion allele, inactive
C457D
-
less active than the wild-type
C457D/A525C
-
similar activity as the wild-type
C457D/E526A
-
decrease in enzyme functionality
C457D/E526C
-
very sensitive to the thiol-reacting agent dodecylmaleimide, specific activity and thermal stability are severely reduced
C457D/E526D
-
no effect on catalytic avtivity
C457D/E526Q
-
no effect on catalytic avtivity
C457G
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
C457G/T509G
-
site-directed mutagenesis, the mutations disrupt the pre-existing H-bond to the protonating Asp456 and the intrinsic His234-Tyr510 H-bond network, respectively, and generates achilleol A as the major product
C703D
-
site-directed mutagenesis, the mutant shows unaltered product spectrum compared to the wild-type enzyme
C703G
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703H
-
site-directed mutagenesis, the mutant generates an unusual truncated bicyclic rearranged intermediate, (8R,9R,10R)-polypoda-5,13E,17E,21-tetraen-3beta-ol, related to iridal-skeleton triterpenoid. Numerous oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are also isolated from the mutant
C703I
-
site-directed mutagenesis, the mutant generates an unusual truncated bicyclic rearranged intermediate, (8R,9R,10R)-polypoda-5,13E,17E,21-tetraen-3beta-ol, related to iridal-skeleton triterpenoid. Numerous oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are also isolated from the mutant
C703N
-
site-directed mutagenesis, the mutant shows unaltered product spectrum compared to the wild-type enzyme
C703S
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703T
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703V
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
F445C
-
produces 10% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 69% lanosterol, 13% parkeol, 8% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445D
-
produces 21% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 63% lanosterol, 11% parkeol, 5% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445M
-
produces 7% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 65% lanosterol, 18% parkeol, 10% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445N
-
produces 10% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 63% lanosterol, 9% parkeol, 18% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445T
-
produces 49% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 46% lanosterol, 5% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F699A/C703I
-
site-directed mutagenesis, inactive mutant
F699C
F699C/I705F
-
the mutant is inactive
F699H
-
the mutant produces lanosterol (13%), protosta-13(17)-dien-3beta-ol (70%), and (17Z)-protosta-17(20),24-dien-3beta-ol (17%)
F699I
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699L
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699M
F699M/C703I
-
site-directed mutagenesis, inactive mutant
F699M/I705F
-
the mutant produces 53% lanosterol, 17% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 12% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 15% protosta-13(17),24-dien-3beta-ol, and 3% 17alpha-protosta-20(22),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
F699N
-
nonviable mutant, does not produce lanosterol, but protosta-13(17)-dien-3beta-ol (55%), malabarica-14E,17E,21-trien-3beta-ol (5%), 17alpha-protosta-20,24-dien-3beta-ol (24%), and (17Z)-protosta-17(20),24-dien-3beta-ol (16%)
F699P
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699Q
-
inactive
F699S
-
inactive
F699T
F699T/C703I
-
site-directed mutagenesis, different oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are isolated from the mutant
F699T/I105F
-
the mutant produces 36% lanosterol, 45% protosta-13(17),24-dien-3beta-ol, 7% 17alpha-protosta-20,24-dien-3beta-ol, and 12% 17alpha-protosta-20(22),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
F699X
-
TKW14[pERG7F699X] site-saturated mutants allow for ergosterol-independent growth, with the exception of Leu, Ile, His, Met, Pro, and Thr substitutions
F699Y
-
inactive
H234A
-
products are 17% protosta-12,24-dien-3beta-ol, 13% protosta-20,24-dien-3beta-ol, 30% lanosterol, 40% parkeol
H234C
-
products are 7% protosta-12,24-dien-3beta-ol, 4% protosta-20,24-dien-3beta-ol, 67% lanosterol, 22% parkeol
H234D
-
products are 58% iso-malabarica-14(16),17,21-trien-3beta-ol, 30% lanosterol, 12% parkeol
H234E
-
products are 49% lanosterol, 51% parkeol
H234F
-
products are 66% achilleol A, 14% lanosterol, 20% parkeol
H234G
-
products are 29% protosta-12,24-dien-3beta-ol, 7% protosta-20,24-dien-3beta-ol, 17% lanosterol, 47% parkeol
H234I
-
products are 70% lanosterol, 30% parkeol
H234K
-
no catalytic activity
H234L
-
products are 39% lanosterol, 31% parkeol, 30% iso-malabarica-14(16),17,21-trien-3beta-ol
H234M
-
products are 17% achilleol A, 10% iso-malabarica-14(16),17,21-trien-3beta-ol, 30% lanosterol, 40% parkeol
H234N
-
products are 23% protosta-12,24-dien-3beta-ol, 14% protosta-20,24-dien-3beta-ol, 27% lanosterol, 10% parkeol, 26% iso-malabarica-14(16),17,21-trien-3beta-ol
H234P
-
products are 64% lanosterol, 36% parkeol
H234Q
-
product is 100% lanosterol, like wild-type
H234R
-
no catalytic activity
H234S
-
product is 100% protosta-12,24-dien-3beta-ol
H234T
-
product is 100% parkeol
H234V
-
products are 42% lanosterol, 58% parkeol
H234W
-
product is 100% parkeol
H234W/Y510V
-
the mutant produces achilleol A, (13H)-isomalabarica-14(26),17E,21-trien-3beta-ol, and lanosterol at a 2:8:90 ratio from (S)-2,3-oxidosqualene
H234W/Y510W
H234Y
-
products are 14% achilleol A, 26% protosta-12,24-dien-3beta-ol, 51% lanosterol, 9% parkeol
H234Y/Y510A
-
the mutant produces lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
I705A
-
the mutant produces 78% lanosterol, 13% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 8% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 0.3% protosta-13(17),24-dien-3beta-ol, and 0.7% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705C
-
the mutant produces 72% lanosterol, 16% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 11.7% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 0.3% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705D
-
the mutant produces 37% lanosterol, 32% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 30% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 1% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705F
-
the mutant produces 25% lanosterol, 21(13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol, 6% 17alpha-protosta-20,24-dien-3beta-ol, 42% 17alpha-protosta-20(22),24-dien-3beta-ol from, and 6% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705G
-
the mutant produces 35% lanosterol, 23% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 34% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 6% protosta-13(17),24-dien-3beta-ol, 1% 17alpha-protosta-20(22),24-dien-3beta-ol and 1% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705K
-
the mutant produces 12% lanosterol, 26.5% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 53.1% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 7.6% protosta-13(17),24-dien-3beta-ol, and 0.8% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705L
-
the mutant produces 100% lanosterol from (3S)-2,3-oxidosqualene (wild-type activity)
I705M
-
the mutant produces 88% lanosterol, 6% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, and 6% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705N
-
the mutant produces 19% lanosterol, 41% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 37% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 3% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705P
-
the mutant produces 81.9% lanosterol, 0.1% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 15% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 3% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705Q
-
the mutant produces 25% lanosterol, 39% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 31% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 5% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705S
-
the mutant produces 12% lanosterol, 42% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 44% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 1% protosta-13(17),24-dien-3beta-ol, and 1%protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705T
-
the mutant produces 22% lanosterol, 36% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 41% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 1% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705V
-
the mutant produces 75% lanosterol, 10% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, and 15% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol from (3S)-2,3-oxidosqualene
Q450H
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme produng exclusively achilleol A as product
Q450H/V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing lanosterol, (13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol, and protosta-16,24-dien-3beta-ol
T384Y
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing lanosterol, parkeol, and 9beta-lanosta-7,24-dien-3beta-ol
T384Y/Q450H
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly parkeol and very low amounts of 9beta-lanosta-7,24-dien-3beta-ol and lanosterol
T384Y/Q450H/V454I
-
site-directed mutagenesis, the mutant produces exclusively reaction intermediate parkeol but not lanosterol as the sole end product
T384Y/V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly parkeol and lower amounts of 9beta-lanosta-7,24-dien-3beta-ol and lanosterol
T509G
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
V454A
-
results in the production of an additional truncated monocyclic achilleol A
V454G
-
results in the production of an additional truncated monocyclic achilleol A
V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly lanosterol and a low amount of (13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol
W232A
-
products are 18.1% protosta-12,24-dien-3beta-ol, 47.1% lanosterol, 34.8% parkeol
W232C
-
products are 18% protosta-12,24-dien-3beta-ol, 31.8% lanosterol, 50.2% parkeol
W232D
-
products are 7.9% protosta-12,24-dien-3beta-ol, 84.8% lanosterol, 7.3% parkeol
W232E
-
products are 14% protosta-12,24-dien-3beta-ol, 49.2% lanosterol, 36.8% parkeol
W232F
-
products are 8.4% protosta-12,24-dien-3beta-ol, 74.4% lanosterol, 17,2% parkeol
W232G
-
products are 8.4% protosta-12,24-dien-3beta-ol, 74.4% lanosterol, 17.2% parkeol
W232H
-
products are 27.8% protosta-12,24-dien-3beta-ol, 35% lanosterol, 37.2% parkeol
W232I
-
products are 23.5% protosta-12,24-dien-3beta-ol, 33% lanosterol, 43.5% parkeol
W232K
-
no catalytic activity
W232L
-
products are 14.5% protosta-12,24-dien-3beta-ol, 27.8% lanosterol, 57.7% parkeol
W232M
-
products are 10.9% protosta-12,24-dien-3beta-ol, 40.6% lanosterol, 48.5% parkeol
W232N
-
products are 10.7% protosta-12,24-dien-3beta-ol, 59.5% lanosterol, 29.8% parkeol
W232P
-
products are 4.4% protosta-12,24-dien-3beta-ol, 82.9% lanosterol, 12.7% parkeol
W232Q
-
products are 24.6% protosta-12,24-dien-3beta-ol, 32.1% lanosterol, 43.3% parkeol
W232R
-
no catalytic activity
W232S
-
products are 10.7% protosta-12,24-dien-3beta-ol, 59% lanosterol, 30.3% parkeol
W232T
-
products are 14.3% protosta-12,24-dien-3beta-ol, 61.7% lanosterol, 24% parkeol
W232V
-
products are 19.3% protosta-12,24-dien-3beta-ol, 34% lanosterol, 46.7% parkeol
W232Y
-
products are 4.2% protosta-12,24-dien-3beta-ol, 94.2% lanosterol, 1.6% parkeol
W587F
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
W587Y
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510A
Y510C
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510F
-
produces lanosterol and isomalabaricatrienol in a 95:5 ratio in strain RXY6, while in strain SMY8, the ratio is 10:90
Y510H
Y510K
Y510L
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510S
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510W
Y707A
-
the mutant produces 18.9% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 56.9% lanosterol, 19.9% 9beta-lanosta-7,24-dien-3beta-ol, and 4.3% parkeol from (S)-2,3-oxidosqualene
Y707C
-
the mutant produces 6% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 47.1% lanosterol, 42.6% 9beta-lanosta-7,24-dien-3beta-ol, and 4.3% parkeol from (S)-2,3-oxidosqualene
Y707D
-
the mutant produces 21.8% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 67.3% lanosterol, 7.6% 9beta-lanosta-7,24-dien-3beta-ol, and 3.3% parkeol from (S)-2,3-oxidosqualene
Y707E
-
the mutant produces 12.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 70.8% lanosterol, 10.5% 9beta-lanosta-7,24-dien-3beta-ol, and 6.4% parkeol from (S)-2,3-oxidosqualene
Y707F
-
the mutant produces 89.2% lanosterol, 3.1% parkeol, and 7.7% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707G
-
the mutant produces 28.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 48.2% lanosterol, 16.3% 9beta-lanosta-7,24-dien-3beta-ol, and 7.2% parkeol from (S)-2,3-oxidosqualene
Y707H
-
the mutant produces 83.6% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 4.7% lanosterol, 6.2% 9beta-lanosta-7,24-dien-3beta-ol, and 5.5% parkeol from (S)-2,3-oxidosqualene
Y707I
-
the mutant produces 87.9% lanosterol and 12.1% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707K
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707L
-
the mutant produces 85.3% lanosterol and 14.7% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707M
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707N
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707P
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707Q
-
the mutant produces 82% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 4.3% lanosterol, and 13.7% parkeol from (S)-2,3-oxidosqualene
Y707R
-
inactive
Y707S
-
the mutant produces 21.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 42.9% lanosterol, 20.5% 9beta-lanosta-7,24-dien-3beta-ol, and 15.3% parkeol from (S)-2,3-oxidosqualene
Y707T
-
the mutant produces 9.8% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 65.1% lanosterol, 13.5% 9beta-lanosta-7,24-dien-3beta-ol, and 11.6% parkeol from (S)-2,3-oxidosqualene
Y707V
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707W
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707X
-
the mutant produces (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, in addition to lanosterol, parkeol, and 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
C457D
-
less active than the wild-type
-
C457D/E526A
-
decrease in enzyme functionality
-
C457D/E526C
-
very sensitive to the thiol-reacting agent dodecylmaleimide, specific activity and thermal stability are severely reduced
-
C457D/E526D
-
no effect on catalytic avtivity
-
C457D/E526Q
-
no effect on catalytic avtivity
-
F699I
-
the mutant produces lanosterol (100%) as the wild type enzyme
-
F699L
-
the mutant produces lanosterol (100%) as the wild type enzyme
-
F699N
-
nonviable mutant, does not produce lanosterol, but protosta-13(17)-dien-3beta-ol (55%), malabarica-14E,17E,21-trien-3beta-ol (5%), 17alpha-protosta-20,24-dien-3beta-ol (24%), and (17Z)-protosta-17(20),24-dien-3beta-ol (16%)
-
F699T
-
the mutant produces lanosterol (less than 0.2%) and protosta-13(17)-dien-3beta-ol (above 99.8%)
-
F699X
-
TKW14[pERG7F699X] site-saturated mutants allow for ergosterol-independent growth, with the exception of Leu, Ile, His, Met, Pro, and Thr substitutions
-
additional information